Healing & Repair
TB-500
Thymosin Beta-4 fragment (TB4 17-23)
Synthetic fragment of Thymosin Beta-4 used in tissue repair research
- FDA Status
- Not FDA-approved · Off-WADA list for sport (banned)
- Class
- Heptapeptide fragment of TMSB4X
- Sequence
- LKKTETQ
- Half-life
- ~2-3 hours
Mechanism of action
- Actin-binding regulator — promotes cell migration and differentiation
- Anti-inflammatory action via IL-1β suppression
- Stimulates angiogenesis through endothelial cell migration
- Induces hair follicle stem cell activity
Research areas
- Equine soft-tissue injury (most documented application)
- Cardiac muscle repair post-infarct (animal data)
- Corneal wound healing
- Hair regrowth (preliminary research)
Evidence and clinical data
Veterinary use in racehorses is well-documented. Human clinical data is sparse. Most TB-500 references in commercial literature confuse the 7-amino-acid synthetic fragment with full-length Thymosin Beta-4 (43 aa) — the two are pharmacologically different.
Safety profile
Not WADA-approved for athletic use (banned in competition). Limited human toxicology data. Known to remain detectable in blood for weeks post-injection.
Why this peptide is trending in 2026: Common stack partner with BPC-157 in injury-recovery protocols. Demand driven by the soft-tissue repair claims, though human evidence remains thin.
Educational use only. PeptideAdvance does not sell TB-500, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.